GLOW70mg
Blend of GHK-Cu, TB-500 (TB4), BPC-157
GLOW Blend Canada — 70 mg Lyophilized Vials
Multi-Peptide Research Blend
GLOW is a multi-compound research blend typically explored for its combined effects on skin-related pathways, cellular turnover, and overall tissue quality in laboratory models. Studies often examine how its components interact to influence collagen activity, oxidative balance, and visible surface-level characteristics within controlled experimental settings.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
GLOW is a multi-peptide research blend formulated for controlled laboratory investigation. It integrates GHK-Cu, BPC-157, and TB-500 into a single experimental compound.
In scientific literature, the individual components of GLOW have been studied in models examining extracellular matrix signaling, angiogenic pathways, and cytoskeletal response systems under in vitro and preclinical research conditions.
GLOW integrates peptides that have been independently examined in structural and signaling research frameworks. GHK-Cu has been studied in extracellular matrix and peptide–metal interaction models, BPC-157 in angiogenic pathway systems, and TB-500 in cytoskeletal and cellular migration research.
Within laboratory environments, the combined formulation is evaluated in experimental systems exploring coordinated peptide interaction across structural and extracellular matrix signaling pathways.
The peptides included in GLOW have been studied across several decades of laboratory research. GHK-Cu was identified in the 1970s, BPC-157 emerged from gastric peptide investigations in the 1990s, and TB-500 developed from thymosin beta-4 research.
GLOW represents a research-based integration of these peptides into a unified formulation for controlled experimental evaluation.
Laboratory investigations involving the individual components of GLOW have explored extracellular matrix signaling, angiogenic pathway models, and cytoskeletal interaction frameworks. Research environments examine multi-peptide pathway dynamics under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on extracellular or matrix. This heading marks where GLOW Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on angiogenic. This heading marks where GLOW Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on cytoskeletal, cellular or migration. This heading marks where GLOW Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Goldstein 2012, Pickart 2008, Sikirić 1993. The work appeared in Expert Opin Biol Ther and J Biomater Sci Polym Ed. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 4 primary papers published between 1993 and 2012 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for GLOW Blend, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
GLOW Blend is also referred to as GLOW blend, the glow stack.
GLOW Blend is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under extracellular matrix signaling models, angiogenic pathway research and cytoskeletal and cellular migration investigations.
The 4 papers cited on this page, published between 1993 and 2012 (1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
The lot code printed on the vial matches the code on the certificate for GLOW Blend. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy GLOW Blend in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
GLOW Blend is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.
Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 60mg of the GLOW peptide blend. Independent third-party testing verifies purity, identity, and batch composition prior to release.
The vial contains only the lyophilized peptide blend. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 19(8):969–988.
PubMedA new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(5):313–327.
PubMedThymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 12(1):37–51.
PubMedThymosin beta4 accelerates wound healing. J Invest Dermatol 113(3):364–368.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
